A peptidomimetic antagonist of the integrin alpha(v)beta3 inhibits Leydig cell tumor growth and the development of hypercalcemia of malignancy.
第一作者:
C P,Carron
第一单位:
Department of Discovery Pharmacology, Searle Research and Development, Monsanto Company, St. Louis, Missouri 63198, USA. cpcarr@monsanto.com
作者:
主题词
动物(Animals);细胞分裂(Cell Division);细胞, 培养的(Cells, Cultured);角膜新生血管化(Corneal Neovascularization);剂量效应关系, 药物(Dose-Response Relationship, Drug);内皮, 血管(Endothelium, Vascular);成纤维细胞生长因子2(Fibroblast Growth Factor 2);人类(Humans);高钙血症(Hypercalcemia);莱迪希细胞瘤(Leydig Cell Tumor);小鼠(Mice);小鼠, 近交BALB C(Mice, Inbred BALB C);小鼠, SCID(Mice, SCID);肿瘤移植(Neoplasm Transplantation);丙酸苯酯类(Phenylpropionates);血小板糖蛋白GPⅡb-Ⅲa复合物(Platelet Glycoprotein GPIIb-IIIa Complex);大鼠(Rats);大鼠, Sprague-Dawley(Rats, Sprague-Dawley);受体, 玻连蛋白(Receptors, Vitronectin);重症联合免疫缺陷(Severe Combined Immunodeficiency)
PMID
9581835
发布时间
2004-11-17
- 浏览25

Cancer research
1930-5页
相似文献
- 中文期刊
- 外文期刊
- 学位论文
- 会议论文